Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008–2019
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVES Lomentospora prolificans is an emerging cause of serious invasive fungal infections. Optimal treatment of these infections is unknown, although voriconazole-containing treatment regimens are considered the treatment of choice. The objective of this study was to evaluate the role of combination antifungal therapy for L. prolificans infections. METHODS We performed a retrospective review of medical records of patients with invasive L. prolificans infection diagnosed between 01/01/2008 - 09/09/2019 and that were documented in the FungiScope® registry of rare invasive fungal infections. We compared clinical outcomes between antifungal treatment strategies. RESULTS Over the study period, 41 patients with invasive L. prolificans infection from eight different countries were documented in the FungiScope® registry. Overall, 17/40 (43%) had treatment response/stable disease and 21/40 (53%) fatal outcome attributed to invasive fungal infection. Combination antifungal therapy was associated with increased 28-day survival (15/24 survived versus 4/16 receiving monotherapy; p=0.027) and the combination voriconazole plus terbinafine trended to be associated with higher rates of treatment success (10/16, 63%, 95%CI 35-85%) compared to other antifungal treatment regimens (7/24, 29%, 95%CI 13-51%, p=0.053). In Kaplan Meier survival analysis there was a higher survival probability in patients receiving voriconazole/terbinafine combination compared to other antifungal regimens (median survival 150 days versus 17 days). CONCLUSIONS While overall mortality was high, combination antifungal treatment, and in particular combination therapy with voriconazole plus terbinafine may be associated with improved treatment outcomes compared to other antifungal regimens for the treatment of invasive L. prolificans infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Buitrago, M. J., Monzon, A., & Rodriguez-Tudela, J. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.917-921.2006 · Cited by 298
Revankar, S. G., Baddley, J. W., Chen, S. C. A., Kauffman, C. A., Slavin, M., Vazquez, J. A., Seas, C., Morris, M. I., Nguyen, M. H., Shoham, S., et al. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx200 · Cited by 67
Self-citation
Cited by
Hoenigl, M., Salmanton-García, J., Walsh, T. J., Nucci, M., Neoh, C. F., Jenks, J. D., Lackner, M., Sprute, R., Al-Hatmi, A. M. S., Bassetti, M., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30784-2 · Cited by 470
Self-citationThe Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
Self-citationDrug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium
Arastehfar, A., Gabaldón, T., Garcia-Rubio, R., Jenks, J. D., Hoenigl, M., Salzer, H. J. F., Ilkit, M., Lass-Flörl, C., & Perlin, D. S. (2020) · Antibiotics · doi:10.3390/antibiotics9120877 · Cited by 292
Self-citationBreakthrough invasive fungal infections: Who is at risk?
Jenks, J. D., Cornely, O. A., Chen, S. C. ‐., Thompson, G. R., & Hoenigl, M. (2020) · Mycoses · doi:10.1111/myc.13148 · Cited by 191
Self-citationKirchhoff, L., Dittmer, S., Buer, J., Rath, P.-M., & Steinmann, J. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106105 · Cited by 61
Self-citation
Metadata
- Authors
- Jenks, J. D., Seidel, D., Cornely, O. A., Chen, S., van Hal, S., Kauffman, C., Miceli, M. H., Heinemann, M., Christner, M., Jover Sáenz, A., Burchardt, A., Kemmerling, B., Herbrecht, R., Steinmann, J., Shoham, S., Gräber, S., Pagano, L., Deeren, D., Aslam, S., Taplitz, R., Revankar, S. G., Baddley, J., Mehta, S. R., Reed, S., Slavin, M. A., & Hoenigl, M.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 26
- Issue
- 6
- Pages
- 784.e1-784.e5
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W3002532337
- Cited by
- 80
- References
- 2
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008–2019. https://app.cochat.ai/papers/10.1016/j.cmi.2020.01.012
- The paper
- Jenks, J. D., Seidel, D., Cornely, O. A., Chen, S., van Hal, S., Kauffman, C., Miceli, M. H., Heinemann, M., Christner, M., Jover Sáenz, A., Burchardt, A., Kemmerling, B., Herbrecht, R., Steinmann, J., Shoham, S., Gräber, S., Pagano, L., Deeren, D., Aslam, S., . . . Hoenigl, M. (2020). Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008–2019. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2020.01.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.